Atrial Fibrillation: A4 study: proof of concept?
The A4 and other similar (small) studies strongly support the launch of major trials of left atrial catheter ablation for the maintenance of sinus rhythm, reduction of cardiovascular hospitalizations and improved survival in patients with symptomatic recurrent atrial fibrillation. Will pharmacological therapies continue to have an important place in the management of atrial fibrillation?
A John
AJ
Camm
Irina
I
Savelieva
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000601:surgery*; D017115:Catheter Ablation / Q000009:adverse effects; D006801:Humans; D015337:Multicenter Studies as Topic; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents